Seneste diskussioner
How do recent 'Buy' and 'Outperform' analyst ratings align with the projected 2025 annual EPS of -$0.36?
What are the specific terms and usage of the $150.0 million Note Purchase Agreement from January 13, 2025?
Does the 0.25 Put/Call Ratio for VSTM reflect bullish sentiment on AVMAPKI FAKZYNJA CO-PACK launch? AI+
Does the 0.25 Put/Call Ratio for VSTM reflect bullish sentiment on AVMAPKI FAKZYNJA CO-PACK launch?
What does VSTM's options flow data indicate about market sentiment for September 2025 expirations? AI+
What does VSTM's options flow data indicate about market sentiment for September 2025 expirations?
What are the commercialization challenges for AVMAPKI FAKZYNJA CO-PACK given $2.1M Q2 2025 revenue? AI+
What are the commercialization challenges for AVMAPKI FAKZYNJA CO-PACK given $2.1M Q2 2025 revenue?
What does the 104.36% implied volatility for VSTM options suggest about market expectations for near-term price movements?
How will the May 8, 2025 FDA approval impact AVMAPKI FAKZYNJA CO-PACK's Q3/Q4 2025 sales?
What are the strategic implications of VSTM dosing the first patient in the U.S. trial for VS-7375 in Q2 2025?
What are the next steps for the registrational Phase 3 study for PDAC, following the positive May 22, 2025 RAMP 205 results?
